DrugMapper


Trade Names:	LATANOPROST XALATAN XELPROS
Synonyms:	Latanoprost Latanoprost (isopropyl ester) Monopost PHXA-41 PHXA41 T-2345 T2345 XA-41 XA41 Xalatan Xelpros
Status:	Approved (1996)
Entry Type:	Small molecule
Molecule Category:	Parent Prodrug
ATC:	S01EE01
UNII:	6Z5B6HVF6O


InChI Key	GGXICVAJURFBLW-CEYXHVGTSA-N
Smile	CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1
InChI	InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C26H40O5
Molecular Weight	432.6
AlogP	4.19
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	13.0
Polar Surface Area	86.99
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	31.0

Action	Mechanism of Action	Reference
AGONIST	Prostanoid FP receptor agonist	FDA

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Ion channel Other ion channel Pore-forming toxins (proteins and peptides)	-	-	-	-	11
Transporter Primary active transporter ATP-binding cassette ABCB subfamily	-	12900	-	-	-

Mesh Heading	Maximum Phase	Mesh ID	Reference
Meniere Disease	2	D008575	ClinicalTrials
Vitiligo	2	D014820	ClinicalTrials

MCS

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend :

Indication

Mechanism of Action

Primary Target

Target Level

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Mixture

Side Effects from Label

Side Effects (PT)

Side effects	Relative Frequency (%)	Labels
Vascular disorders Hyperaemia	5.7
Infections and infestations Upper respiratory tract infection	4.1
Eye disorders Conjunctivitis	3.0
General disorders and administration site conditions Sensation of foreign body	2.8
Vascular disorders Hyperaemia	2.4
Skin and subcutaneous tissue disorders Pruritus	2.0
Eye disorders Vision blurred	2.0
Eye disorders Iris hyperpigmentation	1.7
Infections and infestations Bronchitis	1.6
Skin and subcutaneous tissue disorders Eczema	1.6
Skin and subcutaneous tissue disorders Dermatitis	1.5
Skin and subcutaneous tissue disorders Rash	1.5
General disorders and administration site conditions Sensation of foreign body	1.4
Skin and subcutaneous tissue disorders Eczema	1.3
Infections and infestations Bronchitis	1.1
Eye disorders Conjunctivitis	1.1
Eye disorders Eye pain	1.1
Hepatobiliary disorders Hepatic function abnormal	1.1
Eye disorders Lacrimation increased	1.1
Infections and infestations Urinary tract infection	1.1
Eye disorders Vision blurred	1.1
Hepatobiliary disorders Hepatic function abnormal	0.8
Skin and subcutaneous tissue disorders Pruritus	0.8
Eye disorders Eye pain	0.3
Eye disorders Lacrimation increased	0.3

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Eye disorders	26.82
Nervous system disorders	11.47
General disorders and administration site conditions	9.5
Injury, poisoning and procedural complications	7.32
Respiratory, thoracic and mediastinal disorders	4.96
Investigations	4.09
Musculoskeletal and connective tissue disorders	3.99
Skin and subcutaneous tissue disorders	3.96
Vascular disorders	3.81
Product issues	3.57
Cardiac disorders	3.48
Psychiatric disorders	2.91
Immune system disorders	2.68
Gastrointestinal disorders	2.65
Infections and infestations	2.52

Cross References

Resources	Reference
CAS NUMBER	130209-82-4
ChEBI	6384
ChEMBL	CHEMBL1051
DrugBank	DB00654
DrugCentral	1551
EPA CompTox	DTXSID1041057
FDA SRS	6Z5B6HVF6O
Human Metabolome Database	HMDB0014792
Guide to Pharmacology	1961
KEGG	D00356
PubChem	5311221
SureChEMBL	SCHEMBL24698
ZINC	ZINC000012468792

LATANOPROST

Structure

Physicochemical Descriptors

Pharmacology

Indications

Related Entries

MCS

Scaffolds

Side Effects from Label

Adverse Reactions

Cross References


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70